The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Open accessAbstract
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS: We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS: A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post hoc and prespecified subgroup analyses and meta-analyses of 5 major fibrate trialsdHelsinki Heart Study, Veterans Affairs HDL Intervention Trial, Bezafibrate Infarction Project, FIELD, and ACCORD-Lipiddhave shown a CV benefit in persons with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL, either isolated or together) but not in persons without dyslipidemia.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits in outcome studies appear limited to subgroups with high TG and low HDL-C, highlighting the complexity of translating TG reduction into ASCVD risk reduction [61, 74–77].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, traditional TG-lowering agents, such as fibrates and niacin, have demonstrated inconsistent CVD benefits in randomized trials, even when lipid changes were robust.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the recently concluded AIM-HIGH study did not report any further benefits with regard to cardiovascular events when niacin was added to a statin in patients with median triglyceride level of about 160 mg/dl in the mild hypertriglyceridemia range and average LDL cholesterol levels below 80 mg/dl (177).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“whether lowering these levels would also lower the incidence of cardiovascular events remains controversial.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“These neutral findings with pemafibrate are consistent with those from the contemporary Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) trial 2 of high-dose n-3 fatty acids, the previous Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (160)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies, such as the Copenhagen City Heart Study involving 9330 individuals, indicate a progressive rise in myocardial infarction risk over a decade with increasing Lp(a) levels [13].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [30]
In the citing paper
“Combinations of statins with fibrates, niacin, or fish oil have thus far generally failed to demonstrate cardiovascular benefits beyond that achieved with statins alone.128–132”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [129]
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“In the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but did not reduce the risk of major CV events [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“Niacin also lowers LDL-C levels by 15–20%,49 but recent large randomized trials showed a significant excess of adverse effects and no significant CVD benefit when added to background statin treatment; therefore, niacin derivatives are no longer available for prescription in Europe.50,51”
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Twolarge randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Two large randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Modest regression of carotid atherosclerosis with niacin in most (but not all) imaging studies was not supported by clinical benefit in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Niacin did not reduce stroke over longterm follow-up in patients with CVD in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“With respect to primary endpoints of these studies, although the effectiveness of fenofibrate was not demonstrated, a meta-analysis in primary prevention using fibrates revealed that deaths from cerebrovascular and cardiovascular diseases, non-fatal myocardial infarction, and non-fatal stroke significantly decreased by 16%651).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [651]
In the citing paper
“Combination therapy using ethyl icosapentate (EPA) preparation or fibrate with statin is effective in suppressing ASCVD incidence. (Evidence level 2, recommendation level B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“In a sub-analysis of JELIS study696) which enrolled subjects with hypercholesterolemia, it was shown that EPA administration added-on to statins prevented coronary event incidence for patients in primary prevention whose TG and HDL-C levels were ≥ 151 mg/dL and < 40 mg/dL, respectively.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“Meta-analyses of studies with niacin (mostly without simultaneous administration of statins) indicate a decrease in cardiovascular events [92–94].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [92]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Research works printed but not linked: 1
- Castelli WP, 1988, Can J Cardiol, 4, 5A
Cited by
Sorted by citations
Items 701–800 of 1,019
Iggman, D., Rosqvist, F., Larsson, A. O., Ärnlöv, J., Beckman, L., Rudling, M. J., & Risérus, U. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001095 · Cited by 48
Current concept of reverse cholesterol transport and novel strategy for atheroprotection
Ono, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.014 · Cited by 49
Thacker, S. G., Rousset, X., Esmail, S., Zarzour, A., Jin, X., Collins, H. L., Sampson, M. L., Stonik, J. A., Demosky, S. J., Malide, D. A., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m048629 · Cited by 46
Cardiovascular Disease Risk Assessment and Prevention
Alagona, P., & Ahmad, T. A. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.003 · Cited by 47
Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients
Potočnjak, I., Degoricija, V., Trbušić, M., Pregartner, G., Berghold, A., Marsche, G., & Frank, S. (2017) · Scientific Reports · doi:10.1038/srep46642 · Cited by 46
Chalmers, A. D., Bursill, C. A., & Myerscough, M. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187674 · Cited by 45
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Structural and functional changes in HDL with low grade and chronic inflammation
O'Neill, F., Riwanto, M., Charakida, M., Colin, S., Manz, J., McLoughlin, E., Khan, T. A., Klein, N. J., Kay, C. W. M., Patel, K., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.058 · Cited by 47
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46
The role of high-density lipoproteins in the regulation of angiogenesis
Tan, J. T. M., Ng, M., & Bursill, C. A. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv104 · Cited by 49
Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity
Milman, S., Atzmon, G., Crandall, J. P., & Barzilai, N. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111666131219101551 · Cited by 46
Sibley, C. T., Vavere, A. L., Gottlieb, I., Cox, C., Matheson, M. B., Spooner, A. E., Godoy, G., Fernandes, V., Wasserman, B. A., Bluemke, D. A., et al. (2013) · Heart · doi:10.1136/heartjnl-2013-303926 · Cited by 46
Niiranen, T., & Vasan, R. S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1176528 · Cited by 49
Modulating cholesterol efflux capacity to improve cardiovascular disease
Brownell, N. K., & Rohatgi, A. K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000317 · Cited by 46
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 48
Niacin and heart disease prevention: Engraving its tombstone is a mistake
Superko, H. R., Zhao, X.-Q., Hodis, H. N., & Guyton, J. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.08.005 · Cited by 47
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 46
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006359 · Cited by 45
Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome
Rosenson, R. S., Brewer, H. B., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302805 · Cited by 45
Miselli, M. A., Nora, E. D., Passaro, A., Tomasi, F., & Zuliani, G. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0135-6 · Cited by 45
Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment
Harada, A., Toh, R., Murakami, K., Kiriyama, M., Yoshikawa, K., Miwa, K., Kubo, T., Irino, Y., Mori, K., Tanaka, N. K., et al. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.022913 · Cited by 46
Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention
Ossoli, A., Pavanello, C., Giorgio, E., Calabresi, L., & Gomaraschi, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180316115726 · Cited by 46
From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants
Rhainds, D., & Tardif, J. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000589 · Cited by 46
Dietary cholesterol increases paraoxonase 1 enzyme activity
Kim, D. S., Burt, A., Ranchalis, J., Richter, R. J., Marshall, J. K., Nakayama, K. S., Jarvik, E. R., Eintracht, J. F., Rosenthal, E. A., Furlong, C. E., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p030601 · Cited by 45
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
O’Connell, T. D., Mason, R. P., Budoff, M. J., Návar, A. M., & Shearer, G. C. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa115 · Cited by 45
Bashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 49
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
Chyu, K., & Shah, P. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00187 · Cited by 44
Management of lipid disorders in patients living with HIV
Myerson, M. L., Malvestutto, C., & Aberg, J. A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.473 · Cited by 44
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort
Sung, K.-C., Wild, S. H., & Byrne, C. D. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.02.009 · Cited by 44
Kim, D. S., Burt, A., Rosenthal, E. A., Ranchalis, J., Eintracht, J. F., Hatsukami, T. S., Furlong, C. E., Marcovina, S. M., Albers, J. J., & Jarvik, G. P. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000902 · Cited by 45
Krishnan, S., Huang, J., Lee, H., Guerrero, A., Berglund, L., Anuurad, E., Lebrilla, C. B., & Zivkovic, A. M. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00730 · Cited by 44
The High-Density Lipoprotein Puzzle
Rosenson, R. S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 44
Plasminogen promotes cholesterol efflux by the ABCA1 pathway
Pamir, N., Hutchins, P. M., Ronsein, G. E., Hao, W., Tang, C., Das, R., Vaisar, T., Plow, E. F., Schuster, V. H., Koschinsky, M. L., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92176 · Cited by 45
Gao, S., Hu, G., Li, D., Sun, M., & Mou, D. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103837 · Cited by 44
Wang, Y.-J., Paneni, F., Stein, S., & Matter, C. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.755060 · Cited by 44
Ambegaonkar, B. M., Tipping, D., Polis, A. B., Tomassini, J. E., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.105 · Cited by 44
Uraemic dyslipidaemia revisited: role of high-density lipoprotein
Speer, T., Zewinger, S., & Fliser, D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft080 · Cited by 45
Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
Mani, P., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0521-x · Cited by 47
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
Návar, A. M., Fine, L. J., Ambrosius, W. T., Brown, A. F., Douglas, P. S., Johnson, K., Khera, A. V., Lloyd‐Jones, D. M., Michos, E. D., Mujahid, M. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100430 · Cited by 42
Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?
Razavi, A. C., Jain, V., Grandhi, G. R., Patel, P., Karagiannis, A. D., Patel, N. H., Dhindsa, D. S., Liu, C., Desai, S., Almuwaqqat, Z., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad406 · Cited by 47
Very Large Database of Lipids: Rationale and Design
Martin, S. S., Blaha, M. J., Toth, P. P., Joshi, P. H., McEvoy, J. W., Ahmed, H. M., Elshazly, M. B., Swiger, K. J., Michos, E. D., Kwiterovich, P. O., et al. (2013) · Clinical Cardiology · doi:10.1002/clc.22214 · Cited by 43
Niacin as antidyslipidemic drug
Julius, U. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0478 · Cited by 43
Chandra, A., Neeland, I. J., Das, S. R., Khera, A., Turer, A. T., Ayers, C. R., McGuire, D. K., & Rohatgi, A. K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.015 · Cited by 43
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
Hopewell, J. C., Seedorf, U., Farrall, M., Parish, S., Kyriakou, T., Goel, A., Hamsten, A., Collins, R., Watkins, H. C., & Clarke, R. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12187 · Cited by 43
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J. P., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 45
Franceschini, G., Favari, E., Calabresi, L., Simonelli, S., Bondioli, A., Adorni, M. P., Zimetti, F., Gomaraschi, M., Coutant, K., Rossomanno, S., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.06.007 · Cited by 42
Apro, J., Tietge, U. J. F., Dikkers, A., Parini, P., Angelin, B., & Rudling, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307385 · Cited by 44
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
Edmiston, J. B., Brooks, N. A., Tavori, H., Minnier, J., Duell, B., Purnell, J. Q., Kaufman, T. M., Wójcik, C., Vörös, S., Fazio, S., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.001 · Cited by 43
Apolipoprotein A‐I Modulates Atherosclerosis Through Lymphatic Vessel‐Dependent Mechanisms in Mice
Milasan, A., Jean, G., Dallaire, F., Tardif, J., Merhi, Y., Sorci‐Thomas, M. G., & Martel, C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006892 · Cited by 43
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death
Natarajan, P., Collier, T., Jin, Z., Lyass, A., Li, Y., Ibrahim, N. E., Mukai, R., McCarthy, C. P., Massaro, J. M., D’Agostino, R. B., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.073 · Cited by 45
Li, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 43
Niisuke, K., Kuklenyik, Z., Horvath, K. V., Gardner, M. S., Toth, C. A., & Asztalos, B. F. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000258 · Cited by 45
Shearer, G. C., Pottala, J. V., Hansen, S. N., Brandenburg, V., & Harris, W. S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p022392 · Cited by 42
Singh, S. A., Andraski, A. B., Pieper, B., Goh, W. W. B., Mendivil, C. O., Sacks, F. M., & Aikawa, M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.d061432 · Cited by 42
Kim, D. S., Li, Y. K., Bell, G. A., Burt, A., Vaisar, T., Hutchins, P. M., Furlong, C. E., Otvos, J. D., Polak, J. F., Arnan, M., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002977 · Cited by 42
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 48
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Qin, Y., Ran, L., Wang, J., Yu, L., Lang, H., Wang, X., Mi, M., & Zhu, J. (2017) · Nutrients · doi:10.3390/nu9091037 · Cited by 42
Favari, E., Thomas, M. J., & Sorci‐Thomas, M. G. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000573 · Cited by 42
Zekavat, S. M., Aragam, K. G., Emdin, C. A., Khera, A. V., Klarin, D. M., Zhao, H., & Natarajan, P. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312626 · Cited by 40
Ajala, O. N., Demler, O., Liu, Y., Farukhi, Z. M., Adelman, S. J., Collins, H. L., Ridker, P. M., Rader, D. J., Glynn, R. J., & Mora, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016507 · Cited by 44
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD
Fried, L. F., & Lewis, J. B. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
Mason, R. P., & Eckel, R. H. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.014 · Cited by 43
Introduction to Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_1 · Cited by 45
The HDL lipidome is widely remodeled by fast food versus Mediterranean diet in 4 days
Zhu, C., Sawrey-Kubicek, L., Beals, E., Hughes, R. L., Rhodes, C. H., Sacchi, R., & Zivkovic, A. M. (2019) · Metabolomics · doi:10.1007/s11306-019-1579-1 · Cited by 40
Cartolano, F. D. C., Dias, G. D. F., Miyamoto, S., & Damasceno, N. R. T. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.767535 · Cited by 41
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 41
Elevated Remnant Cholesterol in 25-Hydroxyvitamin D Deficiency in the General Population
Ooi, E. M. M., Afzal, S., & Nordestgaard, B. G. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000416 · Cited by 41
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 44
Drug Therapy for Stable Angina Pectoris
Rousan, T. A., Mathew, S. T., & Thadani, U. (2017) · Drugs · doi:10.1007/s40265-017-0691-7 · Cited by 46
Reversal of coronary atherosclerosis: Role of life style and medical management
Parsons, C. E., Agasthi, P., Mookadam, F., & Arsanjani, R. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.05.002 · Cited by 43
ANGPTL3 Inhibitors ― Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism ―
Geladari, E. V., Tsamadia, P., & Vallianou, N. G. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0442 · Cited by 41
Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies
Santos, H. O., KONES, R. J., Rumana, U., Earnest, C. P., Izidoro, L. F. M., & Macedo, R. C. O. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.002 · Cited by 42
Lorkowski, S. W., Brubaker, G., Rotroff, D. M., Kashyap, S. R., Bhatt, D. L., Nissen, S. E., Schauer, P. R., Aminian, A., & Smith, J. D. (2020) · Biomolecules · doi:10.3390/biom10040551 · Cited by 45
Donato, M., Ferri, N., Lupo, M. G., Faggin, E., & Rattazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218263 · Cited by 44
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2022) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2022.102450 · Cited by 49
NAD+ and Nicotinamide: Sex Differences in Cerebral Ischemia
Siegel, C. S., & McCullough, L. D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.068 · Cited by 42
Zheng, C., & Aikawa, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.999 · Cited by 42
Wu, Z., Lou, Y., Qiu, X., Liu, Y., Lu, L., Chen, Q., & Jin, W. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0118-1 · Cited by 40
“In the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, the addition of niacin to statin therapy did not reduce the rate of cardiovascular events, despite remarkable improvements in HDL-C [87].”
Severe hypertriglyceridemia: Existing and emerging therapies
Malick, W. A., Do, R., & Rosenson, R. S. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108544 · Cited by 45
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Ahmad, W. N. H. W., Sakri, F. H., Mokhsin, A., Rahman, T. H. A., Nasir, N. M., Abdul-Razak, S., Yasin, M. M., Ismail, A. M., Ismail, Z., & Nawawi, H. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116867 · Cited by 40
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 41
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 41
Keen, H. I., Krishnarajah, J., Bates, T. R., & Watts, G. F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.937422 · Cited by 40
Lapergue, B., Dang, B. Q., Désilles, J., Ortiz-Muñoz, G., Delbosc, S., Loyau, S., Louedec, L., Couraud, P., Mazighi, M., Michel, J., et al. (2013) · Stroke · doi:10.1161/strokeaha.112.667832 · Cited by 40
Secondary prevention after coronary artery bypass graft surgery
Kulik, A. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000331 · Cited by 40
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL
Averna, M. R., Stroes, E. S. G., Ogura, M., Postadzhiyan, A., Čerček, M., Calabrò, P., & Suppressa, P. (2017) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(17)30021-1 · Cited by 40
Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL
Hui, N., Barter, P. J., Ong, K. L., & Rye, K. (2019) · Clinical Science · doi:10.1042/cs20190873 · Cited by 40
HDL therapy today: from atherosclerosis, to stent compatibility to heart failure
Sirtori, C. R., Ruscica, M., Calabresi, L., Chiesa, G., Giovannoni, R., & Badimón, J. J. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1694695 · Cited by 41
Williams, K. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320065 · Cited by 41
Dysfunctional high-density lipoprotein: an updated review
Ouyang, F. W., Chiang, H., Hsu, W., Tsai, M.-H., Huang, C.-Y., Remaley, A. T., Akyol, Ö., & Chen, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1713387 · Cited by 40
Ooi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 38
Metadata
- Authors
- The AIM-HIGH Investigators
- Corresponding author
- The AIM-HIGH Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-15
- Volume
- 365
- Issue
- 24
- Pages
- 2255-2267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2165605025
- Semantic Scholar
- d76ac03611110eeffa5c3ad8b47d06f372d84eb6
- Cited by
- 2,911
- References
- 19
- Citations by year
- 2026: 79 · 2025: 90 · 2024: 138 · 2023: 133 · 2022: 138 · 2021: 165 · 2020: 146 · 2019: 181 · 2018: 208 · 2017: 203 · 2016: 264 · 2015: 302 · 2014: 316 · 2013: 333 · 2012: 192
- FWCI
- 280.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- Sanofi
- Genentech
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nicotinic acid, simvastatin, HDL cholesterol, low HDL cholesterol, residual cardiovascular risk, atherosclerotic cardiovascular disease, extended-release niacin, ezetimibe, LDL cholesterol, triglycerides, major adverse cardiovascular events, cardiovascular risk reduction, statin therapy, coronary artery disease, myocardial infarction, ischemic stroke, acute coronary syndrome, revascularization
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Brain Ischemia, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Muscular Diseases, Niacin, Triglycerides, Proportional Hazards Models, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Atherosclerosis, Kaplan-Meier Estimate, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
